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Background: This document presents the American Thoracic
Society clinical practice guidelines for the diagnosis of primary ciliary
dyskinesia (PCD).
Target Audience: Clinicians investigating adult and pediatric
patients for possible PCD.
Methods: Systematic reviews and, when appropriate, meta-analyses
were conducted to summarize all available evidence pertinent to our
clinical questions. Evidence was assessed using the GRADE (Grading
of Recommendations, Assessment, Development and Evaluation)
approach for diagnosis and discussed by amultidisciplinary panel with
expertise in PCD. Predetermined conflict-of-interest management
strategies were applied, and recommendations were formulated,
written, and graded exclusively by the nonconflicted panelists. Three
conflicted individuals were also prohibited from writing, editing, or
providing feedback on the relevant sections of the manuscript.
Results: After considering diagnostic test accuracy, confidence in
the estimates for each diagnostic test, relative importance of test
results studied, desirable and undesirable direct consequences of
each diagnostic test, downstream consequences of each diagnostic
test result, patient values and preferences, costs, feasibility,
acceptability, and implications for health equity, the panel made
recommendations for or against the use of specific diagnostic
tests as compared with using the current reference standard
(transmission electron microscopy and/or genetic testing) for the
diagnosis of PCD.
Conclusions:The panel formulated and provided a rationale for the
direction as well as for the strength of each recommendation to
establish the diagnosis of PCD.
Keywords: primary ciliary dyskinesia; Kartagener syndrome; situs
inversus; nitric oxide; diagnosis
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Question 1: Should an Extended
Genetic Panel (Testing >12
Genes) Be Used as a
Diagnostic Test in Adult and
Pediatric Patients with a High
Probability (At Least Two of
Four Key Clinical Features) of
Having PCD (as a Replacement
of Reference Standards of
Classic TEM Structural Ciliary
Defect and/or Standard
Genetic Panel Testing for
Mutations in <12 Genes
Associated with PCD)?




CF, Be Used as a Diagnostic
Test for PCD in Adult and
Pediatric Patients 5 Years of
Age or Older with a High
Probability (At Least Two of
Four Key Clinical Features) of
Having PCD (as Replacement
of Reference Standards of
Classic TEM Structural Ciliary
Defect and/or Biallelic
Causative Mutations in PCD
Genes)?
Question 3: Should HSVM Alone
Be Used as a PCD Diagnostic
Test in Adult and Pediatric
Patients with a High Probability
(At Least Two of Four Key
Clinical Features) of Having
PCD (as a Replacement of
Reference Standards of
Classic TEM Structural Ciliary
Defect and/or Biallelic Causative
Mutations in PCD Genes)?
Question 4: Should CBF or Ciliary
Waveform Analysis Using Light
Microscopy without High-
Speed Recording Be Used as a
PCD Diagnostic Test in Adult
and Pediatric Patients with a
High Probability (At Least Two
of Four Key Clinical Features)
of Having PCD (as
Replacement of Reference
Standards of Classic TEM
Structural Ciliary Defect and/or




Goals of This Guideline
The purpose of this guideline is to
analyze evidence and present diagnostic
recommendations for primary ciliary
dyskinesia (PCD). The guideline should
empower clinicians to interpret these
recommendations in the context of the
individual patient and make appropriate
clinical decisions about diagnostic tests. For
each recommendation, it is important to
consider both the summary of evidence
reviewed and discussed by members of
the committee, especially patient values
and preferences, before applying these
recommendations to specific clinical
situations or policy decisions.
Clinicians, patients, and other
stakeholders should never view these
recommendations as dictates. No guideline
can account for all clinical circumstances.
The implications of the strength of the
recommendations are described in Table 1.
This guideline applies the same
reference standard for all clinical questions,
but it does not necessarily provide
recommendations for one diagnostic test
over another or advocate for or against
combinations or sequential tests. However, a
suggested diagnostic algorithm for PCD is
provided as part of this document. Strong or
conditional ratings for each recommendation
must be weighed individually (i.e., two
recommendations with the same strong or
conditional rating should not by default be
considered equivalent recommendations),
factoring in all components used to
determine the grade of the recommendation,
including the confidence in accuracy
estimates of each diagnostic test; the relative
importance of test results studied; desirable
and undesirable consequences of each
diagnostic test; and the cost, feasibility,
acceptability, and implications of each
diagnostic test. The methods used by
guideline panels to appraise the evidence
are different from those employed during
regulatory agency reviews of applications
seeking market approval.
From the outset of guideline
development, the workgroup made certain
assumptions. First, with PCD being a
heterogeneous disease, no reference
diagnostic standard is universally accepted.
Thus, the workgroup proposed the
combination of transmission electron
microscopy (TEM) ultrastructural ciliary
defect and/or genetic panel testing for
mutations in known PCD genes as the most
accurate “reference standard” for diagnosing
PCD. Second, per the GRADE (Grading
of Recommendations, Assessment,
Development and Evaluation) approach,
the effects of diagnostic test results on
patient-important clinical outcomes must
be assessed to develop recommendations.
With PCD being a rare disease, frequently
misdiagnosed in past cohorts, and managed
with a wide range of unproven therapies,
the workgroup considered that long-term
effects of appropriate/inappropriate
diagnostic decisions would make modeling
of diagnostic results imprecise. Thus, the
workgroup decided to rank the importance
of the test results, patient-important
outcomes, and overall certainty in the
evidence of effect of the test separately from
the certainty in diagnostic test accuracy.
Introduction
PCD is a genetically heterogeneous,
autosomal recessive disorder characterized
by motile cilia dysfunction. Clinical
manifestations of PCD include chronic
upper and lower airway disease, left–right
laterality defects, and infertility (1–4). The
diagnosis is often delayed, even in children
who have characteristic clinical features of
PCD, in part related to limitations of
available diagnostic tests. For over four
decades, the diagnosis of PCD has been
based on the presence of ultrastructural
defects in the ciliary axoneme using TEM
analysis, which can have serious drawbacks.
Nonspecific ciliary changes, which can be
induced by exposure to environmental
pollutants or infection, may appear similar
as visualized by TEM to findings seen in
PCD. Also, the absence of axonemal defects
does not exclude PCD, because 30% of all
affected individuals have normal ciliary
ultrastructure (5). Other diagnostic tests
have emerged, including nasal nitric oxide
(nNO) measurement, genetic testing, digital
high-speed video microscopy with ciliary
beat pattern analysis (HSVM), and
immunofluorescence imaging for specific
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axonemal proteins. However, there is no
universally agreed-upon “gold standard” for
diagnosis, and no single modality has
sufficient diagnostic sensitivity and
specificity when applied to the general
population (1, 6).
Some clinical features of PCD can
overlap with other conditions, such as cystic
fibrosis (CF), immunodeficiency, pulmonary
aspiration, asthma, and recurrent viral
respiratory infections. However, PCD is not a
diagnosis of exclusion. Recently, investigators
identified four key clinical features
characteristic of PCD (7). 1) Year-round,
daily, productive (wet) cough and 2) year-
round, daily, nonseasonal rhinosinusitis begin
in early childhood, often shortly after birth,
and are almost universally present by
6 months of age. These respiratory symptoms
may vary but never fully resolve, even
after systemic antibiotic therapy (6).
Approximately 80% of children with PCD
have a history of 3) neonatal respiratory
distress syndrome as term newborns, defined
as the need for supplemental oxygen or
positive pressure ventilation support for more
than 24 hours without clear explanation
(6–9). Roughly 40–55% of patients with PCD
have 4) laterality defects (e.g., situs inversus
totalis), whereas other situs anomalies (e.g.,
situs ambiguus), with or without congenital
heart defects, are found in roughly 12% of
affected individuals (4, 10). If two of these
distinguishing features are present, the
sensitivity and specificity for PCD are 80%
and 72%, respectively. If all four are present,
the sensitivity and specificity are 21% and
99%, respectively (7). Chronic otitis media
with effusion is also common in children with
PCD, and many require tympanostomy tube
placement before 5 years of age (8), but this
feature does not distinguish children with
PCD from those who do not have PCD. In
term newborns, the combination of situs
inversus totalis and unexplained neonatal
respiratory distress is highly suggestive of
PCD, even in infants who have not yet
developed chronic respiratory symptoms.
Without at least two of these key features,
patients are unlikely to have PCD, and
further testing is usually unwarranted. Thus,
clinicians should consider diagnostic testing
for PCD only in those patients who truly fit
the clinical phenotype.
Other diagnoses should be considered
on the basis of a detailed clinical history. The
otosinopulmonary features of PCD overlap
with symptoms of CF, another genetic
disorder of mucociliary clearance. Children
with CF typically do not have neonatal
respiratory distress or chronic otitis media,
nor do they have daily cough until lung
disease has significantly progressed.
Nonetheless, children being evaluated for
PCD should undergo sweat chloride testing
at a laboratory certified to perform sweat
chloride measurements. Similarly, various
immunodeficiencies may also present with
chronic upper and lower respiratory tract
infections, though not typically with daily,
year-round symptoms. Depending on the
clinical manifestations, a complete blood
count with leukocyte differential, serum
quantitative immunoglobulin levels,
serological assays for specific antibodies as
a measure of vaccine response, and total
serum complement levels should be
measured. Although this testing does not
fully exclude immune dysfunction, major
deficiencies will usually be identified.
Further evaluation by an immunologist may
be required in some cases. Chronic
aspiration may also manifest as chronic
cough and recurrent pulmonary disease.
Asthma and bronchial hyperreactivity may
coexist with PCD, but they can be further
explored with bronchial provocation testing
or bronchodilator response testing.
Methods
Committee Composition
This guideline committee consisted of 2
cochairs (A.J.S. and V.L.), 2 co–vice-chairs
(S. D. Davis and M.M.), 12 additional
pediatric pulmonologists with PCD
expertise, 5 adult pulmonologists with PCD
expertise, and 1 of each of the following
experts: PCD genetics, cardiology/genetics,
pediatric radiology, pediatric otolaryngology,
and neonatology. There were four
representatives from PCD advocacy groups,
including two adult patients with PCD and
two parents of pediatric patients with PCD.
The committee worked with a health research
methodologist (V.L.) who has expertise in
evidence synthesis and the guideline
development process. This methodologist,
who is a clinician and also has expertise in
clinical diagnostic laboratory tests, conducted
systematic reviews and prepared the evidence




Committee members signed a
confidentiality agreement and disclosed
potential conflicts of interest according to
American Thoracic Society (ATS) policy. All
conflicts were successfully managed. At least
50% of the committee chairs, vice-chairs, and
Table 1. Interpretation of Strong and Conditional Recommendations for Stakeholders (Patients, Clinicians, and Healthcare Policy
Makers)
Implications for Strong Recommendation Conditional Recommendation
Patients Most individuals in this situation would want the
recommended course of action and only a small
proportion would not.
The majority of individuals in this situation would want the
suggested course of action, but many would not.
Clinicians Most individuals should receive the intervention.
Adherence to this recommendation according to the
guideline could be used as a quality criterion or
performance indicator. Formal decision aids are not
likely to be needed to help individuals make decisions
consistent with their values and preferences.
Recognize that different choices will be appropriate for
individual patients and that you must help each patient
arrive at a management decision consistent with his or her
values and preferences. Decision aids may be useful in
helping individuals to make decisions consistent with their
values and preferences.
Policy makers The recommendation can be adopted as policy in most
situations.
Policy making will require substantial debate and
involvement of various stakeholders.
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members were free from industry ties. Twelve
of 30 members with recognized expertise in
PCD (A.J.S., S. D. Davis, S. D. Dell, M.R.,
T.W.F., D.P., M.J., M.R.K., C.M., S.D.S.,
M.W.L., and L.M.) reported ties to industry-
sponsored research as primary investigators
in PCD therapeutic trials; however, these
relationships were easily managed for this
diagnostic guideline, which does not evaluate
PCD therapies. Three members (M.W.L.,
S. D. Davis, and T.W.F.) reported
involvement in clinical trials with a novel
nitric oxide measurement device, and these
members participated in the discussion of the
evidence with the rest of the committee but
were recused from discussions related to the
evidence-to-decision framework as well as
from formulating, writing, and grading
recommendations related to nNO testing.
The conflicted members were allowed to stay
in the same room to provide expert input
while discussions among nonconflicted
members took place; however, the members
could do so only when specifically requested
by nonconflicted members. Adherence
to the rules was strict, with one of the
cochairs (A.J.S.) responsible for monitoring
the discussions for adherence to these rules. The
methodologist also participated in discussions
but was a nonvoting participant.
Meetings and Conference Calls
Face-to-face committee meetings were held
at the ATS annual conferences in Denver,
Colorado (May 2015), and in San Francisco,
California (May 2016), and at the PCD
Foundation conference in Minneapolis,
Minnesota (August 2017). Members who
could not attend were invited to participate via
teleconference. Additional planning meetings
were held regularly over the telephone between
A.J.S. and S. D. Davis. Conference calls and
e-mail correspondence were used to discuss
specific issues requiring input from others.
At the Denver meeting, a group of
committee members (n = 18) discussed the
scope and objectives of the project and
formulated clinically relevant questions,
each dealing with a different diagnostic test.
This process was monitored and approved
by the lead ATS methodologist (J. Brozek).
For each of the four proposed clinical
questions, a subcommittee was responsible
for all remaining steps of the process.
After various editing done via e-mail
communications, the four questions were
finalized during a conference call in
October 2015. At the San Francisco
meeting, committee members (n = 19) met,
evidence summaries were presented and
discussed, and the recommendations were
formulated for three of the four clinical
questions. All meetings were attended by
staff from the ATS documents committee.
One member (D.P.) took detailed notes on
all conversations and decision making
conducted at the meetings. Members who
could not attend were invited to participate
via teleconference (M.L.C. in 2016, five
members in 2017). The first clinical
question, regarding genetic testing, was
revised under the guidance of the
committee methodologist and the lead ATS
methodologist (see FORMULATING CLINICAL
QUESTIONS subsection below). A follow-up
conference call was held in January 2017,
and e-mail communications were finished
by July 2017 to complete the guideline
development for this remaining question.
The final committee meeting in
Minneapolis (n = 19) was held to discuss
the strength of final recommendations,
and greater than 70% agreement through
anonymous online voting was required to
make a strong recommendation. The ATS
provided financial and logistical support for
meetings and conference calls. The views
and interests of the ATS had no influence on
the topics discussed and recommendations
made.
Formulating Clinical Questions
The committee created four questions with
direct relevance to clinical challenges
commonly faced by physicians and patients
surrounding PCD diagnosis. Specific
attention was paid to creating questions that
were relevant to centers without expertise in
PCD, which commonly encounter diagnostic
difficulties with PCD. The committee
identified possible results for each test
evaluated with each question and explicitly
rated their relative importance (from the
perspective of a patient suspected of having
PCD) from not important to critical,
following the approach suggested by the
GRADEworking group for diagnosis (11–14).
Despite providing an indirect link to clinical
outcomes, ranking test results by their
relative importance helps focus attention
on those that are most relevant to patients
and helps resolve or clarify potential
disagreements in decision making. Critical
test results uniformly selected for all four
questions include maximizing true-positive
results as well as limiting false-negative
results, thus favoring tests with high
sensitivity. To this end, the committee
reasoned that delays in diagnosis and
treatment of PCD may be harmful but that
starting nontoxic therapies (such as daily
airway clearance and aggressive antibiotics)
in patients who may not have PCD
(i.e., false-positive results) would be beneficial
(and not harmful) in any chronic suppurative
lung disease, regardless of the underlying
cause. Rankings of all outcomes were agreed
on through consensus of the committee.
The clinical question regarding genetic
testing for diagnosis of PCD was initially
created with three separate subquestions.
These questions were formulated when
commercial genetic testing was not
comprehensive, with panels investigating
only 12 to 19 PCD genes, providing PCD
mutation detection rates estimated at only
50%. However, midway through the first
year of this guideline process, access to
extended genetic panel PCD testing became
commercially available when one company
introduced a 32–PCD gene next-generation
sequencing (NGS) panel, including
deletion/duplication analysis. The new
32-gene panel was estimated to detect at
least 70% of PCD mutations, which is
comparable to properly performed TEM
studies. With the increased access to
extended genetic panel testing, the
committee decided that the question on
genetic diagnosis of PCD should be
reformatted to address the possible benefits
of extended genetic PCD panels because
this would be most useful to clinicians
attempting to diagnose PCD. In January
2017, this genetic testing question was
slightly reformatted to reflect this new goal,
and subquestions were removed. Initially,
this question included scenarios in which
genetic testing would be pursued depending
on nNO testing results. Ultimately, the
subcommittee believed that this pathway
was not clinically relevant, because access
to nNO testing is often not available to
clinicians investigating PCD, and the stand-
alone diagnostic accuracy for PCD genetic
testing is much more relevant to clinicians.
Literature Search
A senior medical librarian (E.G.) designed
a search strategy using medical subject
headings and text words from the title,
abstract, and keyword fields, limited to
human studies and articles in any language.
The following databases were searched from
inception forward: MEDLINE (PubMed),
PubMed (National Library of Medicine),
Embase (Ovid), BIOSIS (Ovid), Web of
AMERICAN THORACIC SOCIETY DOCUMENTS
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Science (Thomson Reuters), Scopus
(Elsevier), Cochrane (Wiley), Africa-Wide
Information (EBSCO), AMED (Ovid), and
Global Health (Ovid) (see the online
supplement). Two updates were made,
in September 2015 and in July 2016.
Additional publications not included in
the search were added individually from
committee members’ personal libraries.
Reviewers evaluated previous meta-analyses
for additional articles. Two reviewers (A.J.S.
and D.P.) screened titles and abstracts
to identify articles for full review and
evaluated the full text of articles deemed
potentially relevant by either reviewer using
predefined inclusion and exclusion criteria.
Articles identified for full-text review were
regrouped by topicality and further
evaluated by each subcommittee according
to inclusion/exclusion criteria specific to
their question. These specific criteria were
agreed on a priori by each subcommittee
and varied between questions.
Disagreement was resolved by group
discussion with the chairs and cochairs.
Evidence Review and Development of
Clinical Recommendations
First, data abstraction occurred independently
and in duplicate (by one subcommittee
member and one chair) for all included studies
for each diagnostic question using predesigned
data abstraction forms that had been piloted
before being used. Disagreements were
resolved through discussion with a third
member. In addition to accuracy, individual
study risk of bias and applicability were
assessed independently by two reviewers
(V.L. and A.J.S.), using the revised Quality
Assessment of Diagnostic Accuracy Studies
(QUADAS-2) tool (15). During the data
extraction phase, authors of accepted articles
were contacted via e-mail if inconsistencies in
the article text or data were found. Author
contact was established to investigate
methods that were unclear; to quantify
reference diagnostic data when not included;
and to clarify contentious issues in PCD
diagnosis, such as inclusion of isolated inner
dynein arm (IDA) defects in the reference
standard of diagnosed PCD. If authors did
not respond to several e-mail attempts or the
imprecision was not resolved, their articles
were excluded from further analysis.
Subsequently, diagnostic test accuracy
estimates were pooled and meta-analyses
performed for each test using Review
Manager version 5.3 (The Cochrane
Collaboration) and STATA version IC 14
(StataCorp) software. For this guideline, we
liberally used the term “diagnostic test
accuracy” when referring to the different
measures used to evaluate the ability of a
test to discriminate between the target
condition and health (such as sensitivity
and specificity or negative and positive
predictive values) rather than the formal
statistical meaning. Pooling and meta-
analyses of study data were performed by
the methodologist (V.L.) when appropriate.
Of note, pooled analysis presented in
this document may at times differ from
other published meta-analyses, owing to
differences in inclusion and exclusion
criteria. The meta-analysis for the clinical
question on the diagnostic accuracy of nNO
was published before finalization of the
related recommendation provided in this
guideline (16).
Evidence tables for each question were
prepared by the methodologist, following
the GRADE approach for diagnosis (11, 13,
17) and using the GRADEpro Guideline
Development Tool online software (18).
The certainty in test accuracy (also known
as confidence in accuracy estimates)
was first assessed as per the GRADE
recommendation for diagnosis—that is,
after evaluating the five domains (risk of
bias, precision, consistency, directness of
the evidence, and other considerations)—
and graded into one of four levels: high,
moderate, low, or very low. All committee
members reviewed the evidence profile
tables, and modifications and additions
were made when appropriate.
Development of recommendations for
each question was based on the GRADE
evidence-to-decision frameworks for
diagnosis using the GRADEpro Guideline
Development Tool online software (18).
This framework helped organize discussion
around each recommendation and ensured
that each of the following factors was
considered: the test accuracy with its
associated certainty, the balance of desirable
and undesirable consequences of compared
diagnostic options, the link between test
results and management decisions, the
effects of the management guided by
the tests results, the overall certainty of the
evidence of effects of the test, the patients’
values and preferences, the implications
for resource use and health equity, the
acceptability of the test to stakeholders, and
the feasibility of implementation (19). The
overall certainty of evidence for each
recommendation (i.e., the certainty of
the effect of testing and subsequent
management decisions on patient-
important outcomes) was assessed
following the GRADE approach for
diagnosis and categorized into one of four
levels: high, moderate, low, or very low
(19). Recommendations and their strength
were decided by consensus through
anonymous online voting by committee
members. The committee agreed on the
final wording of recommendations and
remarks with further qualifications for
each recommendation (e.g., subgroup
considerations, justification, implementation
considerations), and a unified diagnostic
algorithm was created and accepted by the
committee. The recommendations were
either “strong” or “conditional” according to
the GRADE approach (20, 21). As suggested
by GRADE, we used the phrasing “we
recommend” for strong recommendations
and “we suggest” for conditional
recommendations. Table 1 provides
suggested interpretation of these
recommendations by intended stakeholders,
including patients, clinicians, and health
policy makers.
The committee encountered challenges
in adopting strengths of recommendation,
notably for the questions on nNO and
extended genetic panel testing as
replacements of the reference standard. The
analysis for these tests provided moderate
certainty of evidence in diagnostic test
accuracy, and over 70% of committee
members initially voted for “strong”
recommendations in this diagnostic
guideline. However, long-term, patient-
important outcome data are lacking in
PCD, and there is major uncertainty
regarding the impact of PCD diagnosis on
long-term patient health (i.e., very low
certainty in the overall evidence). This led
to the final strengths of recommendation
for nNO and extended genetic panel testing
being downgraded to “conditional”
recommendations, despite the committee’s
(including all PCD stakeholders) opinion
that diagnostic test accuracy should be of
primary importance in the decision-making
process of a diagnostic guideline. This
discrepancy highlights the challenges of
making strong diagnostic recommendations
for rare diseases, because even perfect
diagnostic accuracy will often result in a
conditional recommendation without
long-term outcome data, which does
not exist for many rare diseases. The
committee believed that novel approaches
AMERICAN THORACIC SOCIETY DOCUMENTS
e28 American Journal of Respiratory and Critical Care Medicine Volume 197 Number 12 | June 15 2018
 
to this challenge should be investigated
by the GRADE consortium and other
regulatory bodies overseeing diagnostic
clinical practice guidelines.
Manuscript Preparation
The writing committee (A.J.S., S. D. Davis,
D.P., V.L, J.E.P., and T.W.F.) drafted the
guideline document. The manuscript was
then reviewed by the entire committee.
Feedback was provided primarily through
electronic communication and telephone
conference calls, which included some of the
committee members. The entire committee
(both conflicted and nonconflicted
members) had the opportunity to correct
factual errors, clarify the presentation of
background information or evidence
summaries, and suggest changes to the
rationale sections if they improperly
captured the discussion from the face-to-face
meetings. The wording of recommendations
(including strength and direction) was not
altered once recommendations were finalized
during the face-to-face meetings and
teleconferences. The chairs (A.J.S., S. D.
Davis, M.M., and V.L.) confirmed that the
written version of the guideline reflected the
recommendations made by the committee
members. The same process was followed for
each version of the document. The final





Question 1: Should an Extended
Genetic Panel (Testing >12 Genes) Be
Used as a Diagnostic Test in Adult
and Pediatric Patients with a High
Probability (At Least Two of Four Key
Clinical Features) of Having PCD (as a
Replacement of Reference Standards
of Classic TEM Structural Ciliary
Defect and/or Standard Genetic Panel
Testing for Mutations in <12 Genes
Associated with PCD)?
Background. PCD is a genetically
heterogeneous and predominantly
autosomal recessive disorder caused by
biallelic pathogenic mutations in one of the
many identified PCD causative genes (39 to
date). Each PCD diagnostic test carries
limitations, and those tests dependent on
respiratory mucosal (ciliary) biopsy (TEM,
ciliary beat frequency [CBF], and HSVM)
are encumbered by the need for on-site
high-quality specimen sampling, processing,
and analysis. The widespread lack of local
expertise and resources in ciliary biopsy
testing has made molecular genetic testing
an attractive alternative. Genetic testing for
a Mendelian disease has the added value
of procuring inherently high specificity;
however, sensitivity may be expected to
be lacking in a genetically heterogeneous
disease such as PCD. In a comprehensive
review of the PCD literature in 2015,
Zariwala and colleagues demonstrated that
more than 50% of patients with PCD possess
two pathogenic mutations in trans in a
known PCD causative gene (22). However,
the sensitivity of genetic testing is
anticipated to increase as commercial
diagnostic panels incorporate novel
identified PCD genes. Because genetic
testing for PCD is already available in
Clinical Laboratory Improvement
Amendment–certified laboratories and
costs have been decreasing, the impetus
to consider molecular genetic testing as a
first-line diagnostic test for PCD is
increasing.
Specific methodology. Studies using
multigene panels, with sample sizes of 10 or
more subjects, for diagnostic assessment of
PCD were evaluated. After the initial review
of titles and abstracts (see the online
supplement), 91 records were identified for
full-text review to determine their eligibility
for inclusion in the analysis. The genetic
testing subcommittee members (S. D. Dell,
D.P., M.A.Z., and S.D.S.) agreed on
inclusion and exclusion criteria for full-text
review of all 91 articles (see Figure E1.1 in
the online supplement). The committee
excluded 86 articles from the analysis on
the basis of lack of multigene analysis,
sample size of less than 10 patients, article
addressing only disease carrier frequency,
or lack of genetic testing information (see
Section E1 of the online supplement). Five
articles were eligible for evidence synthesis
(7, 23–26); however, two of these articles
used the same patient cohort (25, 26). Four
studies included only PCD cases and thus
could not provide complete diagnostic
accuracy information (23–26). One cohort
study that evaluated genetic and TEM
testing in a population of patients referred
for suspected PCD was included in the
data analysis (7). When necessary, we
obtained additional data from authors to
compare genetic testing results with our
prespecified reference standard for this
question.
Summary of evidence. In the single
analyzed article, Leigh and colleagues
prospectively evaluated 534 pediatric subjects
referred to a multicenter consortium for high
clinical suspicion of PCD (7). Subjects
invariably had chronic otosinopulmonary
disease symptoms, with CF already ruled out
in most cases. All subjects underwent TEM
and NGS genetic testing of 26 known PCD-
causing genes. Two hundred five participants
were diagnosed as “definite PCD” per our
reference standard of classic TEM structural
ciliary defect and/or standard genetic panel
testing for mutations in up to 12 genes
associated with PCD. Among this cohort of
205 patients with definite PCD, 164 patients
carried two pathogenic variants in a PCD
gene (138 detected with the standard genetic
panel, 26 additional ones detected with
extended genetic panel testing), and 41
patients showed classic TEM defects with
negative extended genetic panel testing. One
hundred eighty-seven were categorized as
“other diagnosis or undefined” (i.e., absence
of classic TEM structural ciliary defect
and/or absence of standard genetic panel
testing for mutations in <12 genes
associated with PCD), among whom 186
participants had a negative 26-gene panel.
The remaining 142 participants with a
compatible PCD clinical phenotype and low
nNO measurements, but no identified TEM
defect or disease-causing gene, were labeled
as “probable/possible PCD.”
The sensitivity for the diagnosis of
“definite PCD” by an extended genetic
panel (.12 genes) in this study was 80%,
indicating that 20% of patients were
diagnosed by TEM alone (without a
causative PCD gene found). Despite the fact
that 142 patients with “possible/probable
PCD” could have been considered to have
true negative results according to our
reference standard, the panel members
believed that these patients probably had
PCD and thus had potential false-negative
results. However, without a clear reference
standard diagnosis, these patients were
excluded from our analysis, and the risk of
bias was increased according to QUADAS-2
(Figures E1.2 and E1.3 and Table E1.1). In a
worst-case scenario, if we were to assume
that all of these patients had false-negative
results, the sensitivity of the extended genetic
panel would considerably decrease to 47%.
The specificity for PCD diagnosis was
99.5% in the analyzed study, indicating that
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0.5% of patients were identified by the
extended panel alone without being detected
by TEM and/or a standard panel of up to 12
genes (our reference standard). Specifically,
one case was considered a “false-positive
result” owing to a positive SPAG1 gene
result on the extended gene panel when
the TEM result was nondiagnostic.
Importantly, nearly all cases of PCD
detected by the extended gene panel, but
missed on the standard panel, were already
detected by TEM defects.
Although we were unable to analyze the
specificity of PCD diagnosis in the four case-
series studies, we were able to calculate
sensitivities of each published extended
genetic panel compared with our
prespecified reference standard. Largely, the
sensitivity of the genetic panel test improved
with the increasing number of genes tested
for PCD. Sensitivities were 71.9% when
testing 12 genes (25), 73.3% when testing 19
genes (23), 54.8% when testing 24 genes
(24), 80% when testing 26 genes (7),
and 93.9% when testing 32 genes with
deletion/duplication analysis (26). The
lower sensitivity of 54.8% with the 24-gene
panel (24) may be due to differences in
population stratification, because PCD
genes included in this panel were similar to
those in other studies. Importantly, two
studies conducted genetic testing in the
same patient population (n = 45 families)
and directly demonstrated increasing
sensitivity as the number of analyzed PCD
genes increased (sensitivity of 71.9% with
12-gene panel increased to sensitivity of
93.9% with 32-gene panel including
deletion/duplication analysis) (25, 26).
Recommendation. In patients
presenting with a strong clinical phenotype
for PCD, we suggest using an extended
genetic panel as a diagnostic test over TEM
ciliary testing and/or standard (<12 genes)
genetic panel testing (conditional
recommendation, moderate certainty of
evidence in test accuracy but very low
certainty in the overall evidence). A
majority of committee members initially
endorsed a strong recommendation for
extended genetic panel testing, based on its
diagnostic accuracy, the benefit of genetic
family planning, and the potential to
identify more rapid pulmonary function
decline and poorer clinical outcomes in
certain genotypes (8). However, without
robust, long-term, patient-important
outcome data, the committee felt compelled
to limit this recommendation to a




encourages the use of extended genetic
panel testing for diagnosis of PCD (Table
E1.2 [evidence-to-decision table]) as a
replacement for standard genetic panels (<12
genes) and/or TEM ciliary testing. With this
recommendation, it is noteworthy that TEM
analyses in the cohort-type study were
processed by one expert technician and
reviewed by blinded investigators at a
specialized PCD research center, where TEM
specimens were suitable for interpretation in
88% of cases (27). Conversely, one tertiary
academic care center reported only 63%
feasibility in clinical TEM testing for PCD
(28), with 37% of clinical cases failing to
have biopsy specimens adequate for TEM
analysis. This report is congruent with other
publications showing poor feasibility for
ciliary TEM testing (ranges of 60–80%
feasibility) at international PCD centers of
excellence (5, 29–31). In addition, these
expert PCD centers require repeat ciliary
biopsies for successful TEM analysis in
11–22% of patients, providing additional
travel and medical costs to tested patients
(29, 30, 32). Furthermore, the potential
for broad variability in the handling,
preparation, and interpretation of even those
specimens that are adequate for TEM
analysis raises concerns that many of the
patients with PCD diagnosed by TEM
defects alone in Leigh and colleagues’ study
(7) would be missed in other clinical centers.
This has been confirmed through TEM
testing in the same multicenter consortium
as Leigh and colleagues, where
approximately 20% of patients diagnosed
by TEM defects at their local clinical
centers lacked the same diagnostic finding
upon repeat TEM testing in the expert
consortium (33). Thus, the actual sensitivity
of extended panel genetic testing is likely
higher than 80% in clinical centers, where
TEM testing for PCD is often fraught
with false-positive, false-negative, and
nondiagnostic specimens. In contrast,
routine phlebotomy for genetic testing is
highly feasible in all clinical centers, does
not require patient travel over long
distances, and should not require repeat
sample acquisition.
In the past several years, exome
sequencing of well-characterized PCD
populations has revealed many PCD-
causing genes (CCNO, MCIDAS, DNAH11,
CCDC65, CCDC164, GAS8, HYDIN, RPGR,
and RSPH1) resulting in normal, near-
normal, or nondiagnostic TEM studies of
respiratory cilia (34–41). However, the
26-gene panel used by Leigh and colleagues
(7) did not include most of these newly
discovered PCD-causing genes associated
with normal TEM studies. The inclusion of
these genes, which are now routinely found
on most commercial PCD genetic panels,
would further increase the sensitivity of
PCD genetic testing over that seen by Leigh
and colleagues. Last, Leigh and colleagues’
study did not include deletion/duplication
analysis of the 26 PCD genes tested.
One study of PCD diagnosis by
molecular genetic testing indicates that
8% of cases may be diagnosed by reflex
deletion/duplication analysis on a 32-gene
panel (26). Thus, the sensitivity of the
extended panel used by Leigh and
colleagues should be considerably higher
with deletion/duplication analysis included.
Currently, some commercially available
NGS genetic panels for PCD diagnosis
include deletion/duplication analysis.
This recommendation to use extended
genetic panel testing rather than TEM ciliary
testing and/or standard (<12 genes) genetic
panel testing was voted by consensus, based
on a very low certainty in the overall
evidence for improved long-term, patient-
important outcomes. The committee
considered the aforementioned variables,
resulting in higher test sensitivity in actual
clinical practice (increasing sensitivity with
newer panels and overestimation of TEM
performance in research), as critically
important for this recommendation. In
addition, PCD stakeholders believed that
this recommendation for extended genetic
panel testing will directly benefit patients
through improved diagnostic success. PCD
stakeholders also appreciated the benefits
that early and accurate genetic PCD
diagnosis may have for long-term clinical
and psychosocial outcomes.
Extended genetic panel testing does
have clinical limitations. First, a negative
panel does not rule out PCD, because some
additional PCD genes are likely yet to be
discovered. Next, only biallelic mutations in
the same PCD gene are disease causing, and
parental gene carrier testingmay be required
to verify that mutations arise in trans.
Variants of unknown significance can
provide nondiagnostic results, and
incorrect interpretation of genetic variants
may result in false-positive or false-negative
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diagnoses. Some regions of PCD-causing
genes are not screened by standard genetic
testing and may result in false-negative
results. Thus, consultation with local
genetic specialists may be required for
interpretation of extended genetic panel
testing. Last, North American, European,
and international health plans will need to
adopt payment policies for PCD genetic
testing in their populations.
Future research opportunities. Further
investigation of possible/probable PCD
cases through genetic sequencing is essential
to finding new PCD-causing genes and
new pathogenic variants in known genes
(including possible intronic or regulatory
region mutations). With the increasing
number of PCD-causing genes included
in commercially available genetic testing
panels, the sensitivity of the accessible
genetic testing will continue to improve.
However, genetic panels must be routinely
and frequently updated to include all newly
discovered PCD-causative genes. Last,
databases listing and explaining the
presenting phenotypes associated with
variants of unknown significance in PCD
genes will be necessary to further elucidate
genotype–phenotype relationships in
people with PCD.
Question 2: Should a Low nNO Level
(Detected with Chemiluminescence
Technology), after Excluding CF, Be
Used as a Diagnostic Test for PCD in
Adult and Pediatric Patients 5 Years
of Age or Older with a High Probability
(At Least Two of Four Key Clinical
Features) of Having PCD (as
Replacement of Reference Standards
of Classic TEM Structural Ciliary
Defect and/or Biallelic Causative
Mutations in PCD Genes)?
Background. nNO levels are reproducibly
reduced (,77 nl/min) in PCD (42), and
given that nNO results are immediately
available at certain centers, these
measurements are often used as a screening
tool for PCD before proceeding to TEM
and/or genetic analysis for confirmatory
diagnostic testing. These latter tests are
expensive, can take weeks to months
to complete, and frequently yield
nondiagnostic results (22, 28). Inexperience
in obtaining biopsy samples can lead to
insufficient cilia for TEM analysis, and
inexperience in processing and
interpretation can lead to false-positive or
false-negative TEM results (28, 43). Finally,
current genetic testing cannot detect
biallelic mutations in all cases of PCD (22).
Specific methodology. Studies were
included if they evaluated, in cooperative
patients (generally >5 yr old) who were
deemed to have a high probability of having
PCD (based on a compatible clinical
phenotype), the accuracy of nNO testing
(index test) compared with the reference
standards of classic TEM ultrastructural
ciliary defect (outer dynein arm defect,
outer dynein arm plus IDA defect, IDA
defect with microtubule disorganization,
radial spoke or central apparatus defect)
and/or biallelic mutations in known PCD
genes. Studies were excluded if any of the
following were present:
1. Fewer than 10 patients with PCD were
included in the recruited population.
2. The index test was inadequate: nNO
measurement used electrochemical
technology (NIOX MINO; Circassia
Pharmaceuticals), only nonvelum
closure techniques were used (tidal
breathing), and/or nasal sampling flow
rates outside the ATS/European
Respiratory Society recommended range
were used (44).
3. The reference standard relied on only a
single HSVM for PCD confirmation
(without a second positive PCD diagnostic
test result or without HSVM after cellular
regrowth in culture) or greater than or
equal to 30% of subjects had nonstandard
TEM defects (unrepeated, isolated IDA
defects without MTD) (43).
4. Diagnostic testing accuracy was either not
provided, not accurate, or not calculable.
5. Index testing was incorporated into the
reference standard.
nNO data from patients with CF were
excluded from the analysis because nearly
one-third of patients with CF can have nNO
levels below the PCD diagnostic cutoff of
77 nl/min (45).
After initial review of 6,204 references
by title and abstract, 76 full-text articles
were assessed for eligibility, of which 65
were excluded (Figure E2.1). Twelve study
populations derived from 11 articles were
included in the quantitative synthesis (4,
42, 46–54) and underwent full-text review
by the subcommittee (M.J., M.R., O.Y.,
A.J.S., and V.L.) (Tables E2.1 and E2.2).
A meta-analysis provided a summary
estimate for sensitivity and specificity and
a hierarchical summary receiver operating
characteristic curve. The QUADAS-2
tool was used to assess study quality,
and the GRADE approach was used to
assess the diagnostic test accuracy of
studies to evaluate the certainty of
evidence (Figures E2.2 and E2.5). Further
details on methodology can be found
elsewhere (16).
Summary of evidence. In 12 study
populations (1,432 patients comprising 524
PCD, 908 non-PCD), with use of a reference
standard of TEM alone or TEM and/or
genetic testing, summary sensitivity was
97.5% (95% confidence interval [CI],
92.8–99.2%), and specificity was 96.4%
(95% CI, 88.6–98.9%) (Figures E2.3 and
E2.4). Excluding studies using TEM alone
as the reference standard, the seven studies
using an extended reference standard of
TEM and/or genetic testing showed a
summary sensitivity of 96.4% (95% CI,
89.4–98.8%) and specificity of 96.2% (95%
CI, 84.2–99.2%) (Figure E2.6 and Table
E2.3). Successful measurements were
obtained in more than 90% of subjects in
this meta-analysis, making this test highly
feasible.
Recommendation. In cooperative
patients 5 years of age or older with a
clinical phenotype consistent with PCD
and with CF excluded, we suggest using
nNO testing for the diagnosis of PCD over
TEM and/or genetic testing (conditional
recommendation, moderate certainty in
test accuracy but very low certainty in the
overall evidence). A majority of committee
members initially endorsed a strong
recommendation for nNO testing, based on
its excellent diagnostic accuracy. However,
without long-term, patient-important
outcome data, the committee revised
this recommendation to a conditional
recommendation.
Comment. Because nNO values may
be transiently decreased with acute viral
respiratory infections or sinusitis, establishing
a low nNO on two separate occasions is
indicated. In patients with a compatible
clinical phenotype and low nNO on two
occasions, a presumptive diagnosis of PCD
may be established; TEM and/or genetic
testing are indicated for clinical prognosis
and to enhance understanding of PCD.
Justification and implementation
considerations. Our recently published
meta-analysis of 12 study populations shows
excellent diagnostic accuracy for nNO as a
PCD diagnostic test, in comparison with the
extended reference standard of TEM and/or
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genetic testing (16). Two prior meta-
analyses have come to similar conclusions
(55, 56). Both TEM and genetic analysis are
imperfect reference standard PCD tests,
with currently estimated sensitivities at 70%
(5, 22, 57); each of these tests detects PCD
cases that can be missed by the other test.
In addition, these reference standard tests
can frequently provide nondiagnostic
results, with up to 40% of clinical biopsies
showing inadequate cilia for TEM analysis
(28–30) and up to 43% of genetic testing
detecting no mutations, monoallelic
mutations, or variants of unknown
significance (24). Conversely, nNO
measurement is a highly feasible test
in cooperative patients (generally >5 yr
old), with successful measurements
accomplished in more than 90% of patients
in this meta-analysis. Failure to obtain
reliable nNO values were secondary to
nasal obstruction, equipment malfunction,
high ambient nitric oxide values, or lack of
patient cooperation. A recent multicenter
cohort study of PCD diagnostic referrals
further suggested that nNO testing is more
accurate than both TEM and/or genetic
testing for a PCD diagnosis because nearly
one-fourth of the referred population
had compatible PCD clinical phenotypes
and low nNO values (after ruling out
CF) but negative extended genetic panel
testing and normal or nondiagnostic TEM
studies (7).
Although nNO testing has been largely
considered a PCD screening test, these
analyses show that nNO has diagnostic
accuracy similar to (and possibly better
than) that of the accepted confirmatory
PCD tests of TEM and/or genetic analysis
(Table E2.4 [evidence-to-decision table])
when used in a population with a high
probability of having PCD (at least two key
clinical PCD features). The use of nNO as a
PCD screening test in general populations
without key clinical PCD features will result
in reduced positive predictive value and is
strongly discouraged. The direct desirable
consequences of using nNO testing instead
of TEM and/or genetic testing outweigh the
undesirable consequences, and the overall
impact of avoiding direct costs and
complications justifies using nNO testing as
a replacement for the reference standards.
The overall rates of false-negative results
(which were considered critical) and false
positive results were small (when using
established, standardized protocols with
chemiluminescence devices), and thus the
downstream consequences were considered
similar between nNO, TEM, and genetic
testing. Nevertheless, despite the reported
high accuracy of nNO in comparison with
the reference standards, nNO might be even
more sensitive than TEM and/or current
genetic testing, thus potentially reducing
false-negative results and their downstream
consequences. Because nNO values may be
decreased with acute viral respiratory
infections or sinusitis, verification of low
nNO values on at least two separate
occasions seems prudent when using this
as a PCD diagnostic test. In cases of
strongly suspected PCD with normal
TEM studies and negative genetic testing,
repeatedly low nNO values may be the
only positive PCD diagnostic test result
and should be verified on at least two
occasions.
Therefore, in individuals 5 years of
age or older, with an appropriate clinical
phenotype for PCD, and when CF is
excluded, the diagnostic accuracy of
nNO measurement (performed with
chemiluminescence devices using
established, standardized protocols) is
comparable to that of TEM and/or genetic
testing. nNO testing is noninvasive,
relatively inexpensive for patients
(after institutions purchase a costly
chemiluminescence analyzer), and provides
immediate results. However, there are
limitations, including the need to travel to
specialized centers that perform the testing,
training of device operators, lack of U.S.
Food and Drug Administration approval
for devices in the United States (and
thus the inability of institutions to gain
reimbursement for clinical testing), and the
lack of test standards for children under
5 years old.
Even with low nNO measures, patients
should still progress to further corroborative
PCD diagnostic studies, including genetic
and/or TEM testing, which may provide
long-term prognostic information (8, 41);
improve the general understanding of PCD;
and account for other respiratory tract
illnesses, including acute sinusitis or viral
infection, which may lead to reduced nNO
values (58–60). PCD stakeholders agreed
on the critical importance of confirming
genetic and/or TEM defects after a
diagnosis is made with nNO measurements.
Patients with biallelic disease-causing
mutations in some genes (e.g., RSPH1) can
have nondiagnostic nNO results. Genetic
testing may also inform family planning.
Finally, defining the PCD genotype may
allow development future mutation-specific
therapies, as occurred in CF (61).
Future research opportunities. Further
research is needed on nNO measurements in
children younger than 5 years of age, who
cannot cooperate with velum closure
maneuvers and therefore perform this
technique through tidal breathing. Additional
research needs include determination of age-
specific distributions of nNO levels in disease
control populations and determination of
appropriate diagnostic cutoffs for tidal
breathing nNO measurements. A major
limitation of nNO measurement is the high
cost of chemiluminescence devices, because
this is the only technology currently
recommended for nNO measurement in
PCD diagnosis (44). Further research
examining the diagnostic accuracy of
portable electrochemical nNO devices
could potentially validate less expensive
alternatives for PCD diagnosis. Last,
further standardization of nNO device
measurement software is required, because
significant differences can occur with
automated online measurement programs
compared with offline operator-driven
protocols (62).
Question 3: Should HSVM Alone Be
Used as a PCD Diagnostic Test in
Adult and Pediatric Patients with a
High Probability (At Least Two of Four
Key Clinical Features) of Having PCD
(as a Replacement of Reference
Standards of Classic TEM Structural
Ciliary Defect and/or Biallelic Causative
Mutations in PCD Genes)?
Background. HSVM is used in a number
of specialized laboratories to diagnose
PCD (50, 63–65). With use of a digital
high-speed video camera attached to a
microscope, beating ciliated epithelial edges
are recorded at frame rates of between 120
and 500 frames per second and are then
replayed at slower rates to view ciliary
motion. Samples can then be evaluated to
assess ciliary function by measuring CBF
and/or ciliary beat pattern (CBP). Recent
expert consensus recommended HSVM
ciliary functional assessment of both CBF
and CBP coupled with TEM as a means of
diagnosing PCD (66). However, conducting
HSVM proves challenging, requiring
significant expertise and training.
Furthermore, this expertise is limited
to a few laboratories in Europe and
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Canada; therefore, clinical applicability is
restricted.
Specific methodology. For this analysis,
studies using HSVM (>120 frames per
second recording) were reviewed. After the
initial appraisal of titles and abstracts,
35 articles were identified for full-text review
by the subcommittee (S. D. Davis, C.M.,
and M.A.C.) (Section 3 of the online
supplement). Agreed-upon exclusion criteria
used for full-text review were 1) fewer
than 10 patients with PCD in the studied
population, 2) index test of HSVM included
in the reference diagnostic standard,
3) HSVM with CBP analysis technique not
used, and 4) unable to calculate sensitivity
or specificity (Figure E3.1). Authors were
contacted via e-mail if exclusion criteria
were unclear. Upon further review by the
committee cochairs (A.J.S. and V.L.), four
articles are included in the quantitative
meta-analysis (50, 63–65).
Summary of evidence. Four cross-
sectional, cohort-type studies consecutively
recruited participants and evaluated the
ability of HSVM to diagnose PCD by CBP
analysis. Two studies were prospective, with
sample sizes of 371 (63) and 34 (50)
participants with suspected PCD. Two were
retrospective, with sample sizes of 231 (65)
and 158 (64) participants. None of the
included studies examined PCD diagnosis
by genetic testing in the reference standard.
Stannard and colleagues (63) evaluated
CBP using nasal ciliated epithelial samples
in 371 participants, with TEM as the
reference standard for PCD diagnosis. Of
the 371 participants, 70 were diagnosed
with PCD on the basis of electron
microscopy. The Stannard group evaluated
CBF, ciliary dyskinesia score, percentage
of dyskinetic edges, and immotility index
to determine abnormal CBP. A ciliary
dyskinesia score greater than 2 was the
most accurate of these HSVM measures,
resulting in sensitivity of 92.5%, specificity
of 97.6%, positive predictive value of 91.2%,
and negative predictive value of 98%.
Papon and colleagues (50) evaluated
HSVM in 34 participants with suspected
PCD, using a reference diagnostic standard
of nNO measurement coupled with TEM
for PCD diagnosis. This group conducted
both qualitative and quantitative analysis
using 12 different HSVM measures. Of the
34 participants, 15 were deemed non-PCD,
10 were diagnosed with definite PCD by
reference standard, and 9 received an
inconclusive diagnosis. On the basis of this
small sample size, the investigators reported
that the use of quantitative HSVM CBP
analysis diagnosed 9 of the 10 patients with
PCD and improved diagnostic accuracy,
whereas qualitative measurements
identified only 7 patients with PCD. In
the inconclusive group of nine patients,
quantitative ciliary analysis identified a
further four and qualitative analysis a
further two with abnormal HSVM who had
low nNO levels. However, on reviewing the
discordant nNO and TEM findings within
individual subjects in this group, genetic
testing would be required to accurately
identify PCD in this group of patients. Of
note, the methodology required to perform
this quantitative analysis is complex and
may not be feasible in a clinical setting.
Using a retrospective cohort of 231
patients referred for PCD in Leicester,
England, Hirst and colleagues (65)
evaluated the utility of HSVM in improving
the diagnosis of PCD after epithelial biopsy
samples were grown under air–liquid
interface tissue culture conditions. This
group used TEM as the diagnostic reference
standard with qualitative HSVM analysis as
the index test. HSVM was performed in
both fresh ciliated samples and later after
cellular regrowth to allow for assessment of
any ciliary functional gain after cell culture.
The results revealed that 28 participants
had definite PCD with diagnostic TEM
defects, and all showed 100% dyskinesia
within biopsy samples on HSVM in the
fresh specimens. However, only 12 of 28
(43%) PCD biopsy samples successfully
regrew in culture, but postculture HSVM
and TEM studies were consistent with the
preculture results. In a separate study, Hirst
and colleagues (64) retrospectively analyzed
HSVM after culture regrowth in 158
participants referred for PCD diagnosis,
using a reference diagnostic standard of
TEM defects, clinical history, or abnormal
ciliary function. However, 73 participants
from one site were excluded from our
analysis because the index test of HSVM
was also incorporated into the reference
diagnostic standard. The investigators
reported that the CBP analyses postculture
confirmed the ciliary phenotype in 100% of
PCD cases, and in some cases, they were
better at identifying abnormal CBP versus
preculture fresh analyses.
The selected studies reported data
(Figure E3.3) for two qualitative parameters of
CBP analysis: either by describing the
percentage of dyskinetic beating cilia on the
epithelial edge (64, 65) or by reporting a
ciliary dyskinesia score for the edge (50, 63).
Overall, the pooled sensitivity and specificity
for all four studies were 97.3% (95% CI,
59.8–99.9%) and 96.5% (95% CI,
63.7–99.8%), respectively. However, the 95%
CI of these diagnostic accuracy results was
extremely large, signifying great variation
in the certainty of these results. This is
illustrated by the summary receiver operating
characteristic curve and 95% CIs (Figure
E3.4)
Because genetic PCD testing was not
performed in any of the studies, it is possible
that the reported accuracy may be
overestimated (Figures E3.2–E3.4 and Table
E3.1). Three of the four studies were
conducted by the same research group in
the United Kingdom; these investigators
are expert at using HSVM as well as the
air–liquid interface tissue culture technique.
The single analyzed study done outside of
the United Kingdom was conducted in a
small sample of patients and demonstrated
much worse diagnostic accuracy. Of
note in this study, the accuracy of the
reference standard used for diagnosis
appeared to vary in PCD and inconclusive
cases.
Recommendation. We suggest not
using CBP analysis by HSVM as a
replacement diagnostic test in patients
with a high probability of having PCD
(conditional recommendation, low
certainty in the diagnostic accuracy of the




assessment (CBF and CBP) by HSVM is
often used as a primary PCD diagnostic tool
in some countries. Experts now recommend
HSVM analysis after cellular regrowth of
tissue samples, but CBP may still be affected
by the manipulation of fresh tissue, leading
to a different functional phenotype after
culture (66–68). Significant technical
expertise and equipment are required to
successfully grow ciliated epithelial
cultures, which often fail to regrow, even at
expert centers (65). If cellular regrowth
cannot be achieved, families must travel
repeatedly to centers of expertise for
multiple biopsies and repeat HSVM
analyses.
There is also a lack of standardization
in HSVM interpretation techniques, with
some centers using various quantitative
functional measures based on qualitative
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assessments, such as immotility index,
percentage of dyskinetic edges, and distance
of ciliary tip traveled, whereas other centers
use mainly qualitative descriptions of beat
pattern, including “stiffness” of cilia and
“failure of bending” along the entire
axoneme. With this lack of standardization
in both sample preparation and CBP
interpretation, the HSVM technique itself is
not easily transferred to other centers (poor
feasibility), and the applicability of the
technique across centers remains poor
(Table E3.2 [evidence-to-decision table]).
Only a few international centers have the
necessary expertise to conduct ciliary
functional analysis with HSVM. Last,
interrater agreement of HSVM beat pattern
analysis is quite poor, even in samples
from healthy control subjects (69). Given
these limitations and the potential for
false-positive and false-negative results
for PCD diagnosis, we suggest not
using CBP assessment with HSVM as a
routine diagnostic tool (Table E3.2).
Despite this, CBP analysis may still have
a role in the assessment of patients with
PCD, because currently there is no
“gold standard” PCD test, and both TEM
and genetic testing have significant
diagnostic limitations. Currently,
HSVM is more appropriate for PCD
diagnosis in expert research settings
until investigators offer significant
clinical advancements in HSVM
feasibility and test standardization.
PCD stakeholders strongly support this




relationships using HSVM may help
investigators elucidate the underlying
mechanisms leading to progressive lung
disease in PCD. However, this will require
standardization of protocols (including
tissue culture conditions) and development
of robust, validated CBP measurements.
Studies comparing HSVM analysis with
TEM defects and PCD-causing gene
mutations may delineate disease
mechanisms and aid PCD diagnosis;
however, this would require participation
by multiple centers to achieve adequate
sample size. To improve general
applicability of HSVM, further research is
indicated which demonstrates that multiple
centers can successfully use this tool when
following validated standard operating
protocols.
Question 4: Should CBF or Ciliary
Waveform Analysis Using Light
Microscopy without High-Speed
Recording Be Used as a PCD
Diagnostic Test in Adult and Pediatric
Patients with a High Probability (At
Least Two of Four Key Clinical
Features) of Having PCD (as
Replacement of Reference Standards
of Classic TEM Structural Ciliary
Defect and/or Biallelic Causative
Mutations in PCD Genes)?
Background. Calculation of CBF has
historically been suggested as a PCD
diagnostic method that can be used with
inexpensive bright-field microscopy and
straightforward recording technology (70, 71).
In addition, some clinicians employ ciliary
waveform analysis without high-speed
recording to diagnose PCD (72–74). Some
academic centers even suggest these tests as
first-line screening, and if results are normal,
further PCD diagnostic testing (such as TEM
or genetic testing) may not be necessary
(75, 76). However, most expert North
American PCD centers avoid CBF
measurement or waveform analysis without
high-speed video recording in PCD, because
several recently discovered genetic forms of
PCD result in normal CBF with only subtle
changes in CBP (77). In addition, most PCD
researchers have migrated from standard-
speed video recording to HSVM because this
method provides more detailed ciliary
waveform information for analysis (see
QUESTION 3 above).
Specific methodology. Studies using
standard-speed video microscopy and
HSVM were evaluated in this analysis, but
when HSVM was used, the analyzed data
were limited to only CBF values, and ciliary
waveform analysis was excluded altogether
if HSVM was used. After the initial review
of titles and abstracts, 51 articles were
identified for full-text review by the question
subcommittee (A.J.S., M.W.L., L.M.). After
agreeing on specific inclusion and exclusion
criteria for the full-text review, the
subcommittee completed a full-text review
of all 51 articles (Figure E4.1). Upon further
review by the committee cochairs (A.J.S.,
V.L.), three articles examining CBF for
PCD diagnosis were included for further
analysis (63, 64, 78). One article addressing
ciliary waveform analysis with standard-
speed video recording was considered for
further examination; yet, this additional
article did not employ currently recognized
PCD reference diagnostic standards and
did not use the reliable methods to
perform ciliary waveform analysis (73).
Thus, no articles addressing ciliary
waveform analysis with standard-speed
video recording were included in the final
analysis.
Summary of evidence. Three cross-
sectional studies addressed this question. All
three used TEM defects as the reference
standard, and none examined patients with
PCD diagnosed by genetics. Two of these
were cohort-type studies, but the only
prospective cohort study, by Stannard and
colleagues, was a single-center study that
examined diagnostic testing accuracy of
CBF in 371 consecutively referred patients
with symptoms of PCD (63). With use of
CBF alone, with a prespecified cutoff value
of 11 Hz to diagnose PCD, approximately
13% of PCD cases were missed on the basis
of TEM studies confirming the diagnosis,
with sensitivity and specificity of 87% and
77%, respectively. The authors offered other
waveform analysis techniques and scoring
systems that perform superior to CBF
measurement alone, but these are all
performed with HSVM and thus were not
considered to answer this specific question
on standard-speed video recording. The
other cohort study, by Hirst and colleagues,
was a retrospective, multicenter analysis
of 73 patients referred for suspicion of
PCD (64). Only patients recruited at the
Leicester site were included in our data
analysis, because the other recruiting
center commonly incorporated the index
test (CBF and ciliary motility assessment)
within the reference standard and
possibly did not perform TEM testing if
ciliary motility was normal. Analysis of
the Leicester patients revealed that CBF
values, at a prespecified cutoff of 10 Hz,
provided 68% and 78% sensitivity and
specificity, respectively, compared with
TEM studies. The third study included a
smaller population and was conducted
retrospectively (78). This showed a low
specificity of CBF compared with TEM
diagnosis of PCD. Because genetic PCD
testing was not performed in any of the
previous studies, it is possible (if not
likely) that reported accuracy was
overestimated (Figures E4.2 and E4.3 and
Table E4.1).
Recommendation. We suggest not
using CBF measurement as a diagnostic test
in patients with a high probability of having
PCD (conditional/weak recommendation,
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At least 2 of the 4 key clinical features for PCD:
             Unexplained neonatal respiratory distress in term infant
             Year-round daily cough beginning before 6 months of age
             Year-round daily nasal congestion beginning before 6 months of age
             Organ laterality defect
Access to nNO testing (with chemiluminescence device and standardized protocol) at specialty center
AND Cooperative patient 5 years old, capable of performing nNO testing maneuver 








- Extended genetic panel testing
    (first line)
-TEM of ciliary ultrastructure
Diagnosis of PCD,
if CF is excluded.














Low nNO level Normal nNO level
Diagnosis of PCD











or referral to PCD
specialty center
Diagnosis of PCD PCD Still Possible
Figure 1. Suggested diagnostic algorithm for evaluating the patient with suspected primary ciliary dyskinesia. *Cystic fibrosis should be ruled out before
performing nNO measurement, as roughly one-third of CF patients can have nNO values below PCD diagnostic cutoffs. nNO measurements should only
be performed with chemiluminescence analyzers using standardized protocols at centers with specific expertise in nNO measurements. Some nNO
analyzers have not received approval from federal agencies worldwide (U.S. Food and Drug Administration and Health Canada have not approved all
chemiluminescence devices for clinical use), which may have implications for clinical implementation. †Genetic panels testing for mutations in more than
12 disease-associated PCD genes, including deletion/duplication analysis. ‡As nNO levels can be significantly decreased by viral respiratory tract
infections, a repeat nNO measurement, at least 2 weeks after the initial low value (expert opinion), is recommended to ensure that the initial low value is not
secondary to a viral process. A normal nNO value upon repeat testing suggests that the patient does not have PCD, as nNO values remain consistently
low in PCD. xMost forms of PCD resulting in normal nNO levels have normal or nondiagnostic electron microscopy studies. Thus, genetic testing is
recommended in these cases. #Or presence of variants of unknown significance. For the purposes of this algorithm, “likely pathogenic” variants and
“pathogenic” variants are grouped together as pathogenic. ¶Additional corroborative testing may provide information on clinical prognosis, further
understanding of the disease, and suggest potential future therapeutic considerations. jjKnown disease-associated TEM ultrastructural defects include
outer dynein arm defects, outer dynein arm plus inner dynein arm (IDA) defects, IDA defects with microtubular disorganization, and absent central pair,
identified using established criteria (1, 6, 13). Of note, the presence of IDA defects alone is rarely diagnostic for PCD. DUp to 30% of PCD cases can have
normal ciliary ultrastructure of electron microscopy (EM). Consider referral to PCD specialty center if there is a strong clinical phenotype but all EM and
genetic testing are negative. CF = cystic fibrosis; nNO = nasal nitric oxide; PCD = primary ciliary dyskinesia; TEM = transmission electron microscopy.
AMERICAN THORACIC SOCIETY DOCUMENTS
American Thoracic Society Documents e35
 
low certainty in the diagnostic accuracy of
the test but very low certainty in the overall
evidence). No recommendation could be
made regarding the use of ciliary
waveform analysis without HSVM as a
diagnostic test for PCD, because no studies
using currently recognized reference
standards were identified by our systematic
review.
Justification and implementation
considerations. This analysis shows that the
diagnostic accuracy of CBF calculation is
poor in comparison with the reference
standard of TEM testing. Although not
meeting inclusion criteria for this analysis,
another study of PCD cases using genetic
testing as the diagnostic reference standard
demonstrated overlapping CBF values
between patients with PCD, healthy control
subjects, and disease control subjects (77).
Furthermore, there are no significant
differences in cost (compared with the
reference standard, when CBF is performed
as part of a larger ciliary motility
assessment with HSVM), direct benefits,
or indirect benefits when using CBF as a
diagnostic test (Table E4.2 [evidence-to-
decision table]). The majority of studies
and recommendations supporting ciliary
motion analysis via CBF or standard-speed
video microscopy were published over
15 years ago (70–73, 79), and since
then, no prospective validation studies
have proven this technique as diagnostic
of PCD.
PCD stakeholders expressed very
strong agreement with this
recommendation because they appreciate
the benefits of early and accurate PCD
diagnosis may have for long-term clinical
and psychosocial outcomes. Stakeholders
also believe it is critically important to
properly diagnose patients with PCD on the
basis of genetics and/or TEM defects in
order to identify criteria causing a continued
decline in this subgroup of patients with
PCD, which may lead to targeted, novel
therapies for this subgroup.
The committee realizes that bright-field
microscopy with CBF measurement is a
feasible and inexpensive test that is sometimes
used in centers lacking experience in PCD.
The committee also realizes that prohibiting
this testing will require referral of potential
patients with PCD to more specialized PCD
centers for definitive diagnosis using more
expensive investigations, such as TEM and
genetic testing. However, with the high rate
of false-negative results of CBF and light
microscopy without HSVM, potential patients
with PCD will continue to receive incorrect
diagnoses if these practices continue. Thus,
centers relying on CBF measurement as their
sole PCD diagnostic tool should refer all
potential patients with PCD to specialized
PCD centers for more reliable diagnostic
testing (Table 4.2).
Future research opportunities. Further
investigation of real-time ciliary waveform
analysis without HSVM, accompanied
by automated waveform and CBF
interpretation software, may provide a role
for real-time light microscopy in the future.
However, with the increasing use of HSVM
recording for ciliary waveform analysis, it
seems doubtful that further research into
non-HSVM waveform analysis will occur.
Conclusions: Proposed
Diagnostic Algorithm
On the basis of our review of available
evidence, we propose a diagnostic
algorithm for patients who have a clinical
phenotype consistent with PCD (Figure 1).
The committee was unable to strongly
recommend a single PCD diagnostic test
and recommends that a panel of diagnostic
tests be applied to diagnose PCD, which
may require referral to a PCD specialty
center to provide comprehensive
evaluation and testing. In addition,
whereas nNO measurements (when
measured correctly) may have diagnostic
accuracy equivalent to that of TEM and
genetic testing, it should not completely
replace these tests in all cases. Rather,
clinicians should appreciate the added
diagnostic value of multiple positive tests,
specifically nNO measurement with
genetics or TEM.
The proposed algorithm represents an
idealized setting in which all diagnostic tests
are accessible to a provider. The authors
recognize, however, that there may be
international differences, and providers
must consider diagnostic options based on
availability. Obviously, the algorithm will
need to be modified with the emergence of
newer tests. n
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23. Djakow J, Kramná L, Dušátková L, Uhlı́k J, Pursiheimo JP, Svobodová T,
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